George D Dalton1, Allyn C Howlett. 1. Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
Abstract
BACKGROUND AND PURPOSE: Signalling networks that regulate the progression of cannabinoid CB(1) receptor-mediated extracellular signal-regulated kinase (ERK) activation in neurons are poorly understood. We investigated the cellular mechanisms involved in CB(1) receptor-stimulated ERK phosphorylation in a neuronal cell model. EXPERIMENTAL APPROACH: Murine N18TG2 neuronal cells were used to analyse the effect of specific protein kinase and phosphatase inhibitors on CB(1) receptor-stimulated ERK phosphorylation. The LI-COR In Cell Western assay and immunoblotting were used to measure ERK phosphorylation. KEY RESULTS: The time-course of CB(1) receptor-stimulated ERK activation occurs in three phases that are regulated by distinct cellular mechanisms in N18TG2 cells. Phase I (0-5 min) maximal ERK phosphorylation is mediated by CB(1) receptor-stimulated ligand-independent transactivation of multiple receptor tyrosine kinases (RTKs). Phase I requires G(i/o) βγ subunit-stimulated phosphatidylinositol 3-kinase activation and Src kinase activation and is modulated by inhibition of cAMP-activated protein kinase A (PKA) levels. Src kinase activation is regulated by the protein tyrosine phosphatases 1B and Shp1. The Phase II (5-10 min) rapid decline in ERK phosphorylation involves PKA inhibition and serine/threonine phosphatase PP1/PP2A activation. The Phase III (>10 min) plateau in ERK phosphorylation is mediated by CB(1) receptor-stimulated, ligand-independent, transactivation of multiple RTKs. CONCLUSIONS AND IMPLICATIONS: The complex expression of CB(1) receptor-stimulated ERK activation provides cellular selectivity, modulation of sensitivity to agonists, and coincidence detection with RTK signalling. RTK and PKA pathways may provide routes to novel CB(1) -based therapeutic interventions in the treatment of addictive disorders or neurodegenerative diseases. LINKED ARTICLES This article is part of a themed section on Cannabinoids in Biology and Medicine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.165.issue-8. To view Part I of Cannabinoids in Biology and Medicine visit http://dx.doi.org/10.1111/bph.2011.163.issue-7.
BACKGROUND AND PURPOSE: Signalling networks that regulate the progression of cannabinoid CB(1) receptor-mediated extracellular signal-regulated kinase (ERK) activation in neurons are poorly understood. We investigated the cellular mechanisms involved in CB(1) receptor-stimulated ERK phosphorylation in a neuronal cell model. EXPERIMENTAL APPROACH: Murine N18TG2 neuronal cells were used to analyse the effect of specific protein kinase and phosphatase inhibitors on CB(1) receptor-stimulated ERK phosphorylation. The LI-COR In Cell Western assay and immunoblotting were used to measure ERK phosphorylation. KEY RESULTS: The time-course of CB(1) receptor-stimulated ERK activation occurs in three phases that are regulated by distinct cellular mechanisms in N18TG2 cells. Phase I (0-5 min) maximal ERK phosphorylation is mediated by CB(1) receptor-stimulated ligand-independent transactivation of multiple receptor tyrosine kinases (RTKs). Phase I requires G(i/o) βγ subunit-stimulated phosphatidylinositol 3-kinase activation and Src kinase activation and is modulated by inhibition of cAMP-activated protein kinase A (PKA) levels. Src kinase activation is regulated by the protein tyrosine phosphatases 1B and Shp1. The Phase II (5-10 min) rapid decline in ERK phosphorylation involves PKA inhibition and serine/threonine phosphatase PP1/PP2A activation. The Phase III (>10 min) plateau in ERK phosphorylation is mediated by CB(1) receptor-stimulated, ligand-independent, transactivation of multiple RTKs. CONCLUSIONS AND IMPLICATIONS: The complex expression of CB(1) receptor-stimulated ERK activation provides cellular selectivity, modulation of sensitivity to agonists, and coincidence detection with RTK signalling. RTK and PKA pathways may provide routes to novel CB(1) -based therapeutic interventions in the treatment of addictive disorders or neurodegenerative diseases. LINKED ARTICLES This article is part of a themed section on Cannabinoids in Biology and Medicine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.165.issue-8. To view Part I of Cannabinoids in Biology and Medicine visit http://dx.doi.org/10.1111/bph.2011.163.issue-7.
Authors: L R Stephens; A Eguinoa; H Erdjument-Bromage; M Lui; F Cooke; J Coadwell; A S Smrcka; M Thelen; K Cadwallader; P Tempst; P T Hawkins Journal: Cell Date: 1997-04-04 Impact factor: 41.582
Authors: Sabine K Schmitz; Cillian King; Christian Kortleven; Vincent Huson; Tim Kroon; Josta T Kevenaar; Desiree Schut; Ingrid Saarloos; Joost P Hoetjes; Heidi de Wit; Oliver Stiedl; Sabine Spijker; Ka Wan Li; Huibert D Mansvelder; August B Smit; Lennart Niels Cornelisse; Matthijs Verhage; Ruud F Toonen Journal: EMBO J Date: 2016-04-07 Impact factor: 11.598
Authors: Joana Reis Pedro; Liane I F Moura; Ângela Valério-Fernandes; Filipa I Baptista; Joana M Gaspar; Bárbara S Pinheiro; Cristina Lemos; Fernanda Neutzling Kaufmann; Carla Morgado; Carla S da Silva-Santos; Isaura Tavares; Samira G Ferreira; Eugénia Carvalho; António F Ambrósio; Rodrigo A Cunha; João M N Duarte; Attila Köfalvi Journal: Brain Res Bull Date: 2020-05-16 Impact factor: 4.077
Authors: Resat Cinar; Grzegorz Godlewski; Jie Liu; Joseph Tam; Tony Jourdan; Bani Mukhopadhyay; Judith Harvey-White; George Kunos Journal: Hepatology Date: 2013-11-18 Impact factor: 17.425
Authors: Bárbara S Pinheiro; Cristina Lemos; Fernanda Neutzling Kaufmann; Joana M Marques; Carla S da Silva-Santos; Eugénia Carvalho; Ken Mackie; Ricardo J Rodrigues; Rodrigo A Cunha; Attila Köfalvi Journal: Brain Res Bull Date: 2016-05-18 Impact factor: 4.077
Authors: Robert B Laprairie; Amina M Bagher; Melanie E M Kelly; Denis J Dupré; Eileen M Denovan-Wright Journal: J Biol Chem Date: 2014-07-18 Impact factor: 5.157